Suchergebnisse - "Dobrolecki, Lacey E"

PubPharm (88)

1

A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma

enthalten in: Journal of hepatology | 2024

von Espinoza, A. | Patel, R. | Patel, K. | +25

2

PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition

enthalten in: Cell reports. Medicine | 2023

von Li, Y. | Dobrolecki, L. | Sallas, C. | +21

3

BCM PDX Portal: An Intuitive Web-based Tool for Patient-Derived Xenograft Collection Management, as well as Visual Integration of Clinical and Omics Data

enthalten in: bioRxiv.org | 2023

von Dowst, H. | McOwiti, A. | Zheng, F. | +14

4

A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer

enthalten in: bioRxiv.org | 2023

von Petrosyan, V. | Dobrolecki, L. | Thistlethwaite, L. | +21

5

Heterogeneity in PHGDH protein expression potentiates cancer cell dissemination and metastasis

enthalten in: bioRxiv.org | 2023

von Rossi, M. | Doglioni, G. | Bornes, L. | +29

6

Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer

enthalten in: Cancer research | 2023

von Gou, X. | Kim, B. | Anurag, M. | +13

CommentIn: Cancer Res. 2023 Oct 2;83(19):3159-3161. - PMID 37779428

7

Interferon-Induced Bone Marrow Stromal Antigen 2 (BST2) Is A Functional Tumor-Initiating Cell Marker In Triple-Negative Breast Cancer

enthalten in: bioRxiv.org | 2023

von Souto, E. | Gong, P. | Landua, J. | +6

8

Interferon-Induced Bone Marrow Stromal Antigen 2 (BST2) Is A Functional Tumor-Initiating Cell Marker In Triple-Negative Breast Cancer

enthalten in: bioRxiv : the preprint server for biology | 2023

von Souto, E. | Gong, P. | Landua, J. | +6

9

Deconvolution of cancer cell states by the XDec-SM method

enthalten in: PLoS computational biology | 2023

von Murillo, O. | Petrosyan, V. | LaPlante, E. | +3

10

RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer

enthalten in: EMBO molecular medicine | 2023

von Ciscar, M. | Trinidad, E. | Perez-Chacon, G. | +23

1
2
3
4
5
6
7
8
9
Nächster »
[9]